Stephen Lucas

INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector including input on Bill C-27, and the means through which advancements can be foreseen and managed. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to health care facilities for health care workers and patients. PERSONAL INFORMATION PROTECTION AND ELECTRONIC DOCUMENT ACT (PIPEDA) PRIVACY PROTECTION OF HEALTH INFORMATION AND THE REGULATORY REVIEW: Improvement to privacy legislation to protect the privacy of health information. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. NET ZERO: Advocate for sustainable health systems in Canada, including reaching net-zero emissions by 2050; advocate for the establishment of a national climate and health secretariat within the federal government to develop a pan-Canadian approach to addressing the impacts of climate change and health; and advocate for a targeted health infrastructure fund as part of the federal government’s long-term plan for public infrastructure. MEDICAL ASSISTANCE IN DYING: Advancing the medical profession’s perspectives on medical assistance in dying. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. INDIGENOUS HEALTH AND RECONCILIATION WITH INDIGENOUS PEOPLES: Implementation of the Calls to Action of the Truth and Reconciliation Commission, including addressing the ongoing structural inequities that marginalize Indigenous Peoples, advancing the inclusion of Indigenous Peoples in societal systems and sectors, including health systems, and committing to collaborative and respectful relationships with Indigenous patients and communities. The CMA is also advocating to increase trust between Ind

BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES: Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of Electronic Health Records and Electronic Medical Records in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to health care facilities for health care workers and patients. PERSONAL

The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs Improve safeguards for Canadian health data Improve labour mobility so physicians can work across the country Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. THE ACQUISITION AND THE DOMESTIC SUPPLY OF PERSONAL PROTECTIVE EQUIPMENT FOR HEALTH CARE PROVIDERS: Ensuring the federal government take additional measures ensure adequate supply, proper distribution, and appropriate usage of personal protective equipment throughout health systems. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector including input on Bill C-27, and the means through which advancements can be foreseen and managed. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to

World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) The government's Science and Technology strategy as it relates to the biopharmaceutical industry Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations Smart Regulations as it relates to the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Proposed pharmacare legislation related to any future national pharmacare program Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products New Substances Notification Regulations as it relates to the biopharmaceutical industry Income Tax Act as it relates to biopharmaceutical products Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19 Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products Canada's Access to Medicines Regime with respect to ensuring that the program allows for the deli

World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) The government's Science and Technology strategy as it relates to the biopharmaceutical industry Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations Smart Regulations as it relates to the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products New Substances Notification Regulations as it relates to the biopharmaceutical industry Income Tax Act as it relates to biopharmaceutical products Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19 Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a b

Brain Canada Foundation is seeking a top-up to its current funding to support the development and application of AI to accelerate research, advance our understanding of the brain, and identify solutions for brain diseases and disorders. Brain Canada Foundation is seeking additional funding to increase the Canada Brain Research Fund, which is currently funded by the Government of Canada, through Health Canada, and which current funding expires March 31, 2028. Brain Canada Foundation wishes to engage the Government on policy development issues related to medical research support, mental health, Indigenous health, and sex and gender diversity in the medical and research fields.

DENTAL CARE FUNDING: discussions around the federal budgetary process and program development with regard to funding of dental care, including the Canadian Dental Care Plan and the Interim Federal Health Program. HEALTH HUMAN RESOURCES: discussions on addressing health human resources challenges within dentistry, including challenges in remote areas, the Canada student loan forgiveness, Canada Student Grant, PGWP for dental assistants, internationally trained dentists, administrative staffing. US Tariffs: working with the federal government to advocate on minimizing the impact of tariffs on access to dental care in Canada. DE-INSURANCE: To discuss the potential impact of the Canadian Dental Care Plan (CDCP) on employer-provided dental coverage and to advocate for a range of strategies that prevent employers from dropping their dental benefits, including but not limited to tax credits and changes in eligibility requirements. TAXATION OF HEALTH BENEFITS: to discuss the negative impact and strain that taxing employer provided health benefits would have on the health of Canadians and on the provincially funded healthcare system. SENIORS ORAL HEALTH: funding and administration of oral health care for seniors living independently and in long term care facilities PRE-BUDGET CONSULTATIONS: Federal investments or taxation changes to improve the oral health care of Canadians and practice environment for dentists PERSONS WITH DISABILITIES: increased funding and federal leadership to improveprovincially funded dental programs for persons with disabilities. PERSONAL INFORMATION PROTECTION AND ELECTRONIC DOCUMENT ACT (PIPEDA): PRIVACY PROTECTION OF HEALTH INFORMATION AND THE REGULATORY REVIEW: Improvement to privacy legislation to protect the privacy of health information ORAL HEALTH RESEARCH, ACCESS AND DATA: increased funding for research and projects to help improve the oral health of Canadians, such as filing of submissions and advocacy for improvements to the Oral Health Access Fund NON INSURED HEALTH BENEFITS: Improvement to the dental program in order to enhance the oral health status of patients accessing the program. NATIONAL TOBACCO CONTROL PROGRAMS: Strengthening Canada's tobacco control strategy MARKETING TO KIDS: Sugar/Healthy Eating: to discuss the importance regarding regulations and legislation, Including Bill C-252, surrounding food and beverage marketing to young children. Healthy Eating: to discuss the issue of food labeling and healthy eating for Canadians and its positive impact on oral health. ISO TECHNICAL COMMITTEE 106: creation of international standards for dental devices and materials INDIGENOUS ORAL HEALTH: Programs and policies related to prevention and care to improve the oral health of Indigenous peoples. HEALTH PROMOTION AND DISEASE PREVENTION: Increased investment and improved regulations to protect and enhance the oral health of Canadians HEALTH INFORMATION TECHNOLOGIES (ELECTRONIC HEALTH RECORDS): Investment and needed regulations to facilitate the development of EHRs in Canada FLUORIDE: promotion of positive public health initiatives and achievements EXCISE TAX ACT: GST AND DENTAL SERVICES: Changes to the application of the GST (zero-rate) on Dental practices DENTAL EDUCATION: Increase funding for Canadian Faculties of Dentistry CHEMICAL MANAGEMENT PLAN: The Challenge Process, with regard to regulation of Bisphenol A in oral health care. CEPA (Canadian Environment Protection Act) - Mercury- ROMS (Risk Management Strategy) with regard to safe disposal of dental amalgam waste. CAPITAL GAINS TAX: to discuss the impact that the recent changes to the capital gains tax regulations have on Canadian dentists and to advocate for amendments and/or exemptions that would mitigate the adverse effects. ANTI INDIGENOUS RACISM IN HEALTH: discussions to promote the Truth and Reconciliation Calls to Action as they relate to Health, such as funding for cultural safety programs in dentistry.

Strengthening Canada's tobacco control strategy and National Tobacco control programs Promotion of positive public health initiatives and achievements Personal Information Protection and Electronic Document (PIPEDA) with regard to improvements to privacy of health information. Oral health programs and policies related to prevention and care of children's oral health in indigenous communities Iso Technical Committee 106 with regard to the creation of international standards for dental devices and materials Investment from the Government of Canada in order to regulate and facilitate the development of Electronic Health Records (EHRs) Increased investment and improved regulations to protect and enhance the oral health of Canadians Indigenous Children Increased funding for research to help improve oral health for Canadians Increased funding for Canadian Faculties of Dentistry with regard to dental education. Increased funding and federal leadership to improve provincially funded dental programs for persons with disabilities Increased funding and administration of oral health care for seniors living independently and in long term care facilities Improvements to non-insured health benefits and dental program in order to enhance the oral health status of patients accessing the program. Excise Tax Act: GST and Dental Services: Changes to the application of the GST (Zero-rate) on Dental Practices Discuss the negative impact and strain that taxing employer provided health benefits would have on the health of Canadian and on the provincially funded healthcare system. Discussions around the federal budgetary process and program development with regard to funding of dental care, including the Canadian Dental Care Plan. As well as pre budget consultation with regard to Federal investments of taxation changes to improve the oral health care of Canadians and practice environment for dentists Discussing the importance regarding regulations surrounding food and beverage marketing to young children, as well as food labeling and healthy eating for Canadians, and its positive impact on oral health Chemical Management Plan: The Challenge process with regards to the regulation of Bisphenol A in oral health care. Canadian Environment Protection Act - Mercury-ROMS (Risk Management Strategy) with regards to safe disposal of dental amalgam waste.

Strengthening Canada's tobacco control strategy and National Tobacco control programs. Promotion of positive public health initiatives and achievements Personal Information Protection and Electronic Document (PIPEDA) with regard to improvements to privacy of health information. Oral health programs and policies related to prevention and care of children's oral health in indigenous communities. Iso Technical Committee 106 with regard to the creation of international standards for dental devices and materials. Investment from the Government of Canada in order to regulate and facilitate the development of Electronic Health Records (EHRs). Increased investment and improved regulations to protect and enhance the oral health of Canadians Indigenous Children. Increased funding for research to help improve oral health for Canadians. Increased funding for Canadian Faculties of Dentistry with regard to dental education. Increased funding and federal leadership to improve provincially funded dental programs for persons with disabilities. Increased funding and administration of oral health care for seniors living independently and in long term care facilities. Improvements to non-insured health benefits and dental program in order to enhance the oral health status of patients accessing the program. Federal Budgetary Process with regards to funding of dental care. As well as pre budget consultation with regard to Federal investments of taxation changes to improve the oral health care of Canadians and practice environment for dentists. Excise Tax Act: GST and Dental Services: Changes to the application of the GST (Zero-rate) on Dental Practices. Discuss the negative impact and strain that taxing employer provided health benefits would have on the health of Canadian and on the provincially funded healthcare system. Discussing the importance regarding regulations surrounding food and beverage marketing to young children, as well as food labeling and healthy eating for Canadians, and its positive impact on oral health. Chemical Management Plan: The Challenge process with regards to the regulation of Bisphenol A in oral health care. Canadian Environment Protection Act - Mercury-ROMS (Risk Management Strategy) with regards to safe disposal of dental amalgam waste.

Discuss increasing incidents of violence against health care workers, prevention, and enforcement of existing laws. Support nursing students through targeted financial support such as paid preceptorships and federal grants. Support internationally educated nurses through establishing a collaborative, multi-stakeholder body hosted by Health Canada, to lead national strategy, planning and coordination for internationally educated nurses' registration, integration and support. Targeted funding of $1 billion as an initial investment to immediately begin to address the current health care workforce crisis experienced by provinces/territories across Canada, with funding focused on short and long-term goals. To achieve patient-centred quality care based on the WHO’s comprehensive health labour markets framework that would be acceptable to, and delivered by, the provinces/territories. Provide sustainable funding so nurses and other healthcare workers have access to mental health supports. In keeping with the recommendations of the Truth and Reconciliation Commission, establish specific targets and timelines for the admission and graduation of First Nations, Métis and Inuit health professionals in all postsecondary institutions and provide funding dedicated to indigenous nurse students. Implementing a Universal single-payer pharmacare program. Fund innovative retention and recruitment programs targeted at early-career, mid-career and late-career nurses. Establish a dedicated coordinating body to address critical health workforce data gaps based on global best practices on health workforce management. Address health workforce shortages through the implementation of a comprehensive, pan-Canadian health human resources strategy, in coordination with the provinces and territories, backed by sufficient funding and with real accountability for achieving desired health outcomes; and address critical data gaps through significantly enhancing existing health workforce data infrastructure to standardize data collection and analysis across workers, sectors and jurisdictions, with links to relevant patient information, healthcare utilization and outcome data, for more fit-for-purpose planning and tools available at the provincial, territorial, regional and training program level. In designing this, Canada should draw on global best practices in health workforce planning including in Australia and New Zealand.

Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance) Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding. Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians. National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada. Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada. Trade-related matters, including policies and tariffs impacting medicines and vaccines. Policies and programs related to the health of new immigrants to Canada. Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030. Engagement with federal officials regarding Health Emergency Readiness Canada. The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients. The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR. Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts. Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework. Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development. Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice. Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions. FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario Engage with government to strengthen the Priority Review for Drug Submissions process. Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engagement with the Government regarding the Strategic Innovation Fund Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply fo

Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Engage with government to strengthen the Priority Review of Drug Submissions process. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Federal role in the health system as it relates to funding, the use of federal spending power, and pan-Canadian priorities, including in the areas of physical and digital infrastructure, health workforce, immigration, aging, older adult care, child and youth health, mental health and substance use, palliative care, cybersecurity, Indigenous health, environment, and data. Advancing Canada’s health research and innovation agenda as it relates to funding, policy and program design, and regulatory matters, including in the areas of clinical trials and development of innovative medical treatments.

Increase investment and access to funding for health research, innovation, knowledge translation and commercialization. Mental health and well-being support and services for the health workforce and Canadian public. Allow direct access to federal funding for academic healthcare organizations (healthcare delivery organizations, research institutes and health authorities). Improve Indigenous health services and access to care for Indigenous people, and continue to act on Truth and Reconciliation Commission recommendations. Improve access and quality of palliative care. Implement national standards for long-term care. Funding and programs to improve healthcare infrastructure energy efficiency and climate and pandemic resiliency. Funding and programs to support virtual care, digital health, and cybersecurity in the health sector. Secure an innovation supercluster in the health and life sciences so that this sector can be supported as one of Canada's world-leading innovation clusters. Funding for cybersecurity resiliency and standards in the health sector. Increase funding to modernize critical physical and digital health infrastructure to support the delivery of health services and health research and innovation. Funding, policies and programs related to clinical trials, medications/drugs and medical devices. Create a more equitable, diverse, inclusive and representative health system that reflects the Canadian population and serves the needs of all Canadians. Implement measures and funding to prevent opioid addiction and overdoses, and to improve access to and implementation of appropriate harm reduction programs and treatments. Federal role in the health system as it relates to the use of federal spending power and the achievement of national objectives. Health services to populations falling under federal jurisdiction, like veterans and certain Indigenous people. Improve the delivery of older adult care in Canada, including a shift to providing more home and community care and creating communities that allow for healthy aging. Implement recommendations from the Industry Strategy Council's "Restart, recover, and reimagine prosperity for all Canadians" report, including policy and program changes and increasing investments in the health and biosciences sector. Implement a national health human resources strategy to address staffing shortages and inadequate level of primary care providers and improve working conditions in the health system.

Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval. Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D. Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program. Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration). Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place. Incentives and programs to attract and support manufacturing activities in Canada Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States. COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic. Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection. Communications regarding the maintenance of domestic supply of essential drug products. Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives. Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection. Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.

Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity. Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies. Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program. Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information. Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada. Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations. Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Food and Drugs Act: Delays in product approvals and changes to existing products. COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs. Communication to officials on labelling and product monographs. Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products. Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives. Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas. Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.

Advocacy on the creation of the Health Emergency Readiness Canada (HERC) Agency Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025. Advocacy on the proposed Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays. The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability. Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines. Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and C64, An Act to Implement pharmacare. Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy. Discussions on the procurement of a COVID19 vaccine and therapy Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States. Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.